 USA TODAY | NICE recommends earlier use of Roche's RoActemra for rheumatoid arthritis PMLiVE ... for people with RA as a third-line treatment option if DMARDs had been ineffective, and if patients had also both demonstrated an inadequate response to one or more TNF inhibitors and could not take another Roche drug, MabThera (rituximab). Green light for earlier use of rheumatoid arthritis drug |
